(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 June 2004 (10.06.2004)

PCT

(10) International Publication Number
WO 2004/047866 A3

(51) International Patent Classification[7]: A61K 45/00, 38/22, 31/506, G01N 33/68, A61P 29/00

(21) International Application Number:
PCT/IB2003/005429

(22) International Filing Date:
26 November 2003 (26.11.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20020100513 26 November 2002 (26.11.2002) GR

(71) Applicant *(for all designated States except US)*: **BIONATURE E.A. LIMITED** [CY/CY]; 1 Poseidon, 2406 Egomi, Nicosia (CY).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **MARGIORIS, Andrew, N.** [GR/GR]; c/o University of Crete, School of Medicine, P.O. Box 2208, GR-710 03 Heraklion (GR). **GRAVANIS, Achille** [GR/GR]; c/o University of Crete, School of Medicine, P.O. Box 2208, GR-710 03 Heraklion (GR).

(74) Agents: **ROTNE, Jens, Styrup** et al.; Internationalt Patent-Bureau A/S, Høje Taastrup Boulevard 23, DK-2630 Taastrup (DK).

(81) Designated States *(national)*: AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, EG, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT (utility model), PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
29 July 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/047866 A3

(54) Title: USE OF THE CORTICOLIBERIN-UROCORTIN SYSTEM IN THE TREATMENT OF INFLAMMATORY DISEASES

(57) Abstract: The invention relates to the use of corticotropin-releasing hormone (CRH) receptor-1 (RI) antagonists and/or CRH-R2 receptor agonists for the treatment of inflammatory diseases via regulation of monocyte / macrophage cell activation, proliferation, differentiation, apoptosis, and inflammatory cytokine production. As CRH system we define natural and synthetic CRH and urocortin (UCN) agonists and antagonists for the CRH-R1 and CRH-R2 receptors and their subtypes as well as the CRH-binding protein (BP), a CRH pseudo receptor. The invention is directed towards pharmacological intervention for the amelioration or treatment of inflammatory diseases using the CR. system-mediated control of monocyte / macrophage cells which play a key role in initiating and maintaining the inflammatory response via production of pro-inflammatory cytokines such as is the interleukin (IL)-1, IL-6 and tumor necrosis factor (TNF)-alpha. By the term inflammation we define the response of an organism to noxious endogenous or exogenous stimuli causing tissue injury. Inflammation is a host defence mechanism, which might harm the defending organism. The invention also provides methods for the in vitro and in vivo evaluation of natural and synthetic CRH system modulators for the control of the monocyte / macrophage system.